[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Korea University Guro Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":261},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,77,106,131,160,183,205,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640617","quantitative-chest-ct-and-multi-omics-to-distinguish-asthma-from-copd-and-predict-treatment-response-100640617",false,"NCT07602192","Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response","Prospective Multicenter Cohort to Discriminate Asthma Versus Chronic Obstructive Pulmonary Disease and Predict Treatment Response Using Quantitative Chest CT and Multi-Omics","CTOMICS","Inclusion Criteria:\n\n* Age ≥19 years\n* COPD group: post-bronchodilator FEV1\u002FFVC \\\u003C 0.70\n* Asthma group: clinically confirmed diagnosis of asthma by a physician\n* Able to provide voluntary written informed consent\n\nExclusion Criteria:\n\n* Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks\n* Pregnancy or breastfeeding\n* Inability to undergo chest CT (e.g., poor cooperation or severe medical condition)\n* Refusal to consent to study procedures","ALL","19 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data.\n\nAdults with asthma or COPD will be enrolled and undergo routine clinical evaluations, pulmonary function tests, blood tests, and chest CT scans. Additional samples, such as sputum and microbiome specimens, may also be collected. No experimental drugs or devices will be administered as part of this study.\n\nResearchers will analyze CT imaging features together with clinical, laboratory, and biological data to better distinguish asthma from COPD and to identify factors that may predict treatment response. The findings are expected to contribute to more precise and personalized management of chronic airway diseases.",[25,26],"Asthma (Diagnosis)","COPD (Chronic Obstructive Pulmonary Disease)",[28,29,30,31,32],"Quantitative chest CT","Airway disease","Asthma","Chronic Obstructive Pulmonary Disease","Treatment response","RECRUITING","2026-05-20",{"date":36,"type":37},"2026-05-22","ACTUAL",{"date":39,"type":37},"2025-12-22",{"date":41,"type":21},"2027-12-22",{"name":43,"class":44},"Korea University Guro Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100608205","oct-guided-stent-optimization-for-short-duration-dual-antiplatelet-therapy-in-stable-angina-100608205","NCT07198529","OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina","Optical Coherence Tomography for Stent Optimization and Its Impact on Short-Duration Dual Antiplatelet Therapy: A Single-Center, Prospective, Exploratory Study","COMFORT-SHORT","Inclusion Criteria:\n\n* Patients who undergo PCI using a cobalt-chromium everolimus-eluting stent (CoCr-EES)\n* Diagnosis of stable angina\n* Ability and willingness to provide written informed consent approved by the Institutional Review Board (IRB), and to comply with the study protocol and clinical follow-up schedule\n* Age ≥ 19 years\n\nExclusion Criteria:\n\n* Patients diagnosed with acute coronary syndrome (ACS), including unstable angina or acute myocardial infarction\n* Contraindications to antiplatelet therapy or OCT imaging\n* Presence of lesions with severe stenosis, heavy calcification, or marked vessel tortuosity that prevent passage of a guidewire or catheter\n* Patients with previously implanted coronary stents in the target lesion",{"count":55,"type":21},130,"INTERVENTIONAL",[58],"NA","This study aims to evaluate whether the use of optical coherence tomography (OCT), an advanced intravascular imaging tool, can improve stent implantation results and make it possible to shorten the duration of dual antiplatelet therapy (DAPT) in patients with stable angina who undergo percutaneous coronary intervention (PCI).\n\nPCI with drug-eluting stents is a standard treatment for patients with stable angina, and these patients are usually prescribed DAPT for 6 to 12 months to prevent stent thrombosis and other complications. However, extended use of DAPT increases the risk of bleeding, which can lead to significant medical problems, especially in patients with high bleeding risk.\n\nOCT provides detailed, high-resolution images of the coronary arteries and the implanted stents, allowing physicians to optimize stent expansion and positioning. By ensuring that the stent is well-placed and fully expanded, OCT guidance may lower the risk of complications, potentially reducing the need for prolonged DAPT.\n\nIn this prospective study, patients with stable angina who require stent implantation will be enrolled and treated with OCT-guided PCI followed by a short course of DAPT. Their outcomes will be compared with those managed using conventional strategies.\n\nThe primary goal of this trial is to determine whether OCT-guided stent optimization can safely support a short-duration DAPT strategy, thereby reducing bleeding risk without compromising protection against ischemic events such as restenosis, myocardial infarction, or stent thrombosis.",[61,62],"Stable Angina","Coronary Artery Disease",[64,65,66,67,68],"Optical coherence tomography","stable angina","dual antiplatelet therapy","stent optimization","percutaneous coronary intervention","2025-12-11",{"date":71,"type":37},"2025-12-17",{"date":73,"type":37},"2025-09-30",{"date":75,"type":21},"2029-09",{"name":43,"class":44},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":56,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100600819","evaluation-of-an-opioid-stewardship-program-in-non-cancer-patients-100600819","NCT07102446","Evaluation of an Opioid Stewardship Program in Non-Cancer Patients","Inclusion Criteria:\n\n* Outpatients at the Department of Anesthesiology and Pain Medicine or the Department of Physical Medicine \\& Rehabilitation of the study site who received a prescription for opioid analgesics (oral, transdermal, sublingual, or buccal formulations containing oxycodone, fentanyl, tapentadol, hydrocodone, or morphine) due to chronic non-cancer pain during the study evaluation period (from IRB approval date to September 30, 2025)\n* Adults aged ≥19 years and \\\u003C80 years\n* Patients who voluntarily signed a written informed consent form after receiving a full explanation of the study and understanding its purpose\n\nExclusion Criteria:\n\n* Patients with active cancer\n* Patients diagnosed with sickle cell disease\n* Patients diagnosed with a life-limiting illness eligible for hospice or palliative care as defined in Article 2 of the 'ACT ON HOSPICE AND PALLIATIVE CARE AND DECISIONS ON LIFE-SUSTAINING TREATMENT FOR PATIENTS AT THE END OF LIFE'\n* Pregnant patients\n* Patients who were prescribed opioid analgesics within the past month for postoperative pain management\n* Patients who were prescribed opioid analgesics within the past month for newly developed pain\n* Patients with communication difficulties\n* Patients who were prescribed buprenorphine for the treatment of opioid use disorder\n* Patients who are deemed inappropriate for study participation at the discretion of the investigator","79 Years",{"count":85,"type":21},70,[58],"The objective of this prospective, non-randomized clinical trial is to evaluate the effectiveness of a pharmacist-led Opioid Stewardship Program (OSP) in outpatient adults with chronic non-cancer pain. This study compared OSP implementation with a historical control to determine whether it reduces the incidence of high-risk opioid prescribing and improves patients' awareness, knowledge, and attitudes about opioid use.",[89,90,91,92],"Pain","Chronic Pain","Opioid Analgesia","Opioid Use",[94,95,96,97],"Pharmacist","Pain Management","Opioid Stewardship","Non-Cancer Pain","2025-07-28",{"date":100,"type":37},"2025-08-03",{"date":102,"type":37},"2025-06-27",{"date":104,"type":21},"2026-06",{"name":43,"class":44},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":113,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":56,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100502007","phase-2-comparison-of-clinical-efficacy-between-letrozole--ribociclib-and-fulvestrant--letrozole--ribociclib-in-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-100502007","NCT05816655","Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer","Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer - a Randomized, Phase 2 Study","Inclusion Criteria:\n\n* Female ≥ 19 years of age\n* Histologically confirmed unresectable, locally advanced or metastatic invasive breast cancer with hormone receptor positive\u002FHER2 negative\n* No previous history of systemic endocrine or chemotherapy for metastatic, advanced breast cancer.\n* If the patient has received AI as adjuvant endocrine therapy, the treatment free interval (TFI) should be more than 12 months after the end of adjuvant endocrine therapy. If the patient has received tamoxifen for adjuvant endocrine therapy, TFI less than 12 months will be allowed.\n* ECOG PS 0-2\n* Patients should have measurable or evaluable lesion based on RECIST version 1.1\n* Patients should have adequate organ function:\n\n  * ANC (absolute neutrophil count) ≥ 1.5 × 109\u002FL\n  * Platelet ≥ 100 × 109\u002FL\n  * Serum Hb ≥ 9.0 g\u002FdL\n  * INR ≤1.5\n  * Serum creatinine ≤ 1.5 X ULN\n  * ALT \\& ALT \\\u003C2.5 X ULN, if patients have hepatic metastasis, ALT \\& ALT \\\u003C5.0 X ULN is allowed\n  * Total serum bilirubin \\\u003C1.5 X ULN, if patients have hepatic metastasis, Total serum bilirubin \\\u003C3.0 X ULN is allowed.\n* In the case of childbearing potential, patients who can adhere to appropriate contraception during the study period and for at least 6 months after the end of study treatment.\n* Patients who understand the contents of the clinical trial and are cooperative with the process of the clinical trial.\n\nExclusion Criteria:\n\n* Patients with a history of previous treatment with a CDK4\u002F6 inhibitor or other systemic treatment for advanced\u002Fmetastatic breast cancer\n* Patients who have received prior treatment with fulvestrant and any investigational ER-directed therapy including SERDs (selective estrogen receptor degrader)\n* Patients who have disease recurrence on aromatase inhibitor treatment as adjuvant endocrine therapy\n* Patients who have symptomatic or untreated central nervous system metastasis\n* Patients who have a history of cardiovascular disease or heart failure as following conditions; within at least 6 months of myocardial infarction, unstable angina, or uncontrolled arrhythmia.\n* Patients having visceral crisis which needs rapid tumor reduction\n* Patients who have a history of any other cancer (except nonmelanoma skin cancer, carcinoma in-situ of the cervix, well-differentiated thyroid cancer)\n* Patients unable to cooperate with periodic blood samples collection\n* Patients who have active HBV, HCV infection, immune-suppressive disease, or HIV infection. In case of chronic HBV infection, HBV DNA should be negative. Patients with complete remission of HCV infection are allowed.\n* Pregnant or breast-feeding women\n* Patients who are considered to be unsuitable for this trial by investigators.","FEMALE","80 Years",{"count":116,"type":21},202,[118],"PHASE2","Aromatase inhibitor (AI) + CDK4\u002F6 inhibitor is settled down as the standard first line therapy for HR+\u002FHER2- metastatic breast cancer and all three CDk4\u002F6 inhibitors, palbociclib, ribociclib, and abemaciclib are currently available for same indications. However, there is no effective treatment strategy for patients who have progressed on AI+CDK4\u002F6 inhibitor. In particular, the clinical efficacies of subsequent hormone therapy are lowered when ESR1 mutations, one of mechanisms of AI resistance occur. In the PADA-1 trial, when ESR1 mutations in ctDNA were detected in patients treated with AI+CDK4\u002F6 inhibitor, AI was switched to fulvestrant even if disease progression was not confirmed clinically. As a result, the median PFS was prolonged by about 8 months in this switching group compared to the group in which AI was continued. The results of this study suggested that delaying the occurrence of ESR1 mutations and early response to them are necessary to increase the effectiveness of hormone therapy.\n\nIn SWOG S0226 study, fulvestrant + AI combination showed significant benefits in PFS and OS compared to AI monotherapy as the first line therapy. Based on these results, the NCCN guideline suggests fulvestrant + AI combination as one of the first line hormone therapy options. However, the clinical effect of AI + fulvestrant + CDK4\u002F6 inhibitor has not been investigated yet. Therefore, the investigators are planning to compare the clinical efficacy of AI+ fulvestrant + CDK4\u002F6 inhibitor and AI+CDK4\u002F6 inhibitor, and to investigate if a triple combination regimen can delay the emergence of ESR1 mutations and modulate occurred ESR1 mutations.",[121],"Metastatic Breast Cancer","2025-03-13",{"date":124,"type":37},"2025-03-18",{"date":126,"type":37},"2023-05-31",{"date":128,"type":21},"2029-06-30",{"name":43,"class":44},2,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":113,"minAge":139,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":56,"phases":142,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":45},"100493397","phase-2-secondary-cytoreductive-surgery-crs-in-patients-with-relapsed-ovarian-cancer-who-have-progressed-on-parp-inhibitor-maintenance-100493397","NCT05704621","Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance","A Randomized Phase II Study of Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance","SOCCER-P","Inclusion Criteria:\n\n* Patients with first recurrence of platinum sensitive, invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer of any initial stage.\n* Progression-free interval of at least 6 months after end of last platinum- containing therapy,\n* Progressed during PARP inhibitor maintenance\n* Women aged ≥ 18 years\n* Complete resection of the tumor seems possible (estimated by an experienced surgeon). Intra-abdominal disease has to be excluded by MRI\u002FCT, if other surgical approaches for isolated extra-abdominal recurrences are planned\n\n  1. A positive AGO-score or iMODEL+PET\u002FCT\n  2. Patients who are likely to be completely resected according to the investigator's judgment will be allowed by consensus between PI(surgeon) and designated radiologist even if AGO or iMODEL+PET\u002FCT negative.\n* Patients who have given their signed and written informed consent and their consent to data transmission and -processing.\n\nExclusion Criteria:\n\n* Patients with non-epithelial tumors as well as borderline tumors.\n* Patients without recurrence who are scheduled for diagnostic\u002Fsecond-look surgery or debulking surgery after completion of chemotherapy\n* More than one prior chemotherapy\n* Patients with second, third, or later recurrence\n* Patients with second malignancies who have been treated by laparotomy, as well as other neoplasms, if the treatment might interfere with the treatment of relapsed ovarian cancer or if major impact on prognosis is expected.\n* Patients with so-called platinum-refractory tumor, i.e. progression during chemotherapy or recurrence within 6 months after end of former first platinum- containing therapy\n* Only palliative surgery planned\n* Radiological signs suggesting metastases not accessible to surgical removal (i.e. complete resection is deemed impossible)\n* Any concomitant disease not allowing surgery and\u002For chemotherapy\n* Any medical history indicating excessive peri-operative risk\n* Any current medication inducing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents, bevacizumab)\n* No assessable archival tumor tissue","18 Years",{"count":141,"type":21},124,[118],"This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.",[145,146],"Ovarian Cancer","Drug Related Neoplasm\u002FCancer",[148,149,150,151],"recurrent ovarian cancer","PARP inhibitor resistance","secondary cytoreductive surgery","progression during PARP inhibitor maintenance","2025-03-03",{"date":154,"type":37},"2025-03-06",{"date":156,"type":37},"2023-12-01",{"date":158,"type":21},"2028-12-28",{"name":43,"class":44},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":56,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":45},"100490907","two-channel-iv-pca-with-dexmedetomidine-100490907","NCT05672225","Two-channel IV-PCA With Dexmedetomidine","Effectiveness of Two-channel Intravenous Patient-controlled Analgesia With Dexmedetomidine on Postoperative Opioid Consumption After Major Laparoscopic Abdominal Surgery","Inclusion Criteria:\n\n* Patients who was scheduled for laparoscopic major abdominal surgery (Gastrectomy, Hepatectomy, Colectomy, Pancreatectomy) under general anesthesia\n* Aged ≥ 20 years old\n\nExclusion Criteria:\n\n* Body mass index ≥35 kg\u002Fm2\n* American Society of Anesthesiologists physical status \\> 3\n* Severe cardiovascular disorder\n* Severe liver or renal dysfunction\n* Preoperative dyspnea\n* Contraindication to dexmedetomidine (preoperative severe bradycardia (Heart rate \\\u003C50), atrioventricular block, allergy to dexmedetomidine)\n* Preoperative use of opioid, anticonvulsant, antidepressant","20 Years",{"count":169,"type":21},110,[58],"Dexmedetomidine was administered in the 'selector' channel and fentanyl in the 'basic \\& bolus' channel of dual channel intravenous patient-controlled analgesia (IV-PCA) and the amount of opioid consumption was compared. In addition, intensity of pain, postoperative nausea\u002Fvomiting, and postoperative delirium was evaluated.",[173,174],"Analgesia, Patient-Controlled","Dexmedetomidine","2025-01-02",{"date":177,"type":37},"2025-01-03",{"date":179,"type":37},"2023-02-07",{"date":181,"type":21},"2025-12-31",{"name":43,"class":44},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":204,"locationsCount":45},"100503930","impact-of-ces1-genotype-on-remimazolam-100503930","NCT05841667","Impact of CES1 Genotype on Remimazolam","A Clinical Study to Explore the Effect of Carboxylesterase 1 (CES1) Genotype on Pharmacokinetics, Safety, and Efficacy of Remimazolam","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status 1 or 2\n* Age 19-70 years\n* Elective surgery\n\nExclusion Criteria:\n\n* Concomitant regional anesthesia\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg)\n* Uncontrolled diabetes mellitus (HbA1c \\>9.0%)\n* Aspartate transaminase (AST), Alanine transferase (ALT), Total bilirubin \\> more than 2 times the normal upper limit\n* Estimated glomerular filtration rate \\\u003C60 ml\u002Fmin\u002F1.73m2\n* Moderate to severe chronic pulmonary obstructive disease or respiratory failure\n* Emergency\n* Hepatectomy, Liver transplantation\n* Cardiopulmonary bypass use\n* Craniotomy due to head trauma, unstable intracranial pressure, or brain disease\n* Use of benzodiazepine medications (if tolerance is present)\n* Anxiety, alcohol\u002Fdrug dependence, or addiction to tricyclic antidepressants\n* Reported hypersensitivity and adverse reactions to benzodiazepines, flumazenil, and other agents used during anesthesia\n* Lactose-related genetic disorders\n* Myasthenia gravis or myasthenia gravis syndrome\n* Newly diagnosed myocardial infarction\u002Fclinically significant coronary artery disease, cerebral ischemic attack\u002Fstroke within 6 months, or significant untreated coronary artery disease\n* Implanted rate-responsive cardiac pacemaker with a bioelectrical impedance sensor.\n* Intrinsic brain disorders or other conditions that make it difficult to determine the depth of anesthesia through EEG measurements (e.g., epilepsy)\n* History of severe allergies\n* Cognitive impairment that prevents comprehension of the instructions and consent form of this study, in case of sedation\n* Expected intraoperative blood loss of 1000 ml or more\n* Judged by the investigator to be unsuitable for participation in this study due to other reasons","70 Years",{"count":192,"type":21},120,"Remimazolam is primarily metabolized via CES1, and other drugs that are commonly metabolized by CES1 are known to have their pharmacokinetics and clinical effects affected by genetic polymorphisms in CES1.\n\nThe goal of this observational study is to investigate the impact of the CES1 genotype on the pharmacokinetics, safety, and efficacy of remimazolam in patients undergoing elective surgery.",[195,196,197],"Adult","Middle Aged","Elective Surgical Procedures","2024-10-09",{"date":200,"type":37},"2024-10-15",{"date":202,"type":37},"2023-09-06",{"date":181,"type":21},{"name":43,"class":44},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":213,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":56,"phases":216,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":223,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100531660","sp-robotic-versus-vats-anatomical-pulmonary-resection-for-patients-with-nsclc-100531660","NCT06202690","SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC","Single-POrt Robotic Versus Video-assisted Thoracic Surgery Anatomical Pulmonary Resection for Patients With Non-small Cell Lung Cancer (SPORTS Study): a Single-center, Single-blinded, Randomized Controlled Trial","SPORTS","Inclusion Criteria:\n\n* Candidate for anatomical pulmonary resection (segmentectomy or lobectomy) via minimally invasive thoracic surgery (RATS or VATS) for patient with non-small cell lung cancer or suspected malignant lesion.\n* Age ≥ 18 years\n* Patients who can comply with the requirements of the clinical trial and who, or their legal representatives, provide written consent before the start of the clinical trial\n* Patients with the nationality of South Korea\n* American Society of Anesthesiologists score 1-3.\n* Clinical stage I, II or IIIa non-small cell lung cancer (NSCLC)\n\nExclusion Criteria:\n\n* Patients who require surgery for accompanying other organ diseases\n* Tumor invasion into the chest wall, diaphragm, another lobe or diaphragm\n* Patients who are considered unsuitable based on the researcher's judgment\n* Patients with cognitive impairments who are unable to understand the instructions and informed consent of this study\n* Patients who specifically desire a certain surgical method (robotic, thoracoscopic, open thoracotomy)\n* Patients who previously undergone a thoracic surgical procedure in the hemithorax to be operated on\n* Pathological results other than NSCLC (ex, benign nodules, metastatic lung cancer, SCLC)\n* Patients who received neoadjuvant therapy.\n* Candidate for pneumonectomy, bilobectomy, lobectomy plus segmentectomy, non-anatomic resection (ex, wedge resection).\n* History of other cancers in the past 5 years.",true,{"count":215,"type":21},290,[58],"Single-POrt Robotic-assisted thoracic surgery versus single-port video-assisted Thoracic Surgery major pulmonary resection for patients with non-small cell lung cancer (SPORTS trial): a single-center, a single blinded, randomized controlled trial",[219,220],"Robotics","Lung Cancer",[222],"sing-port surgery, robotic-assisted thoracic surgery, lung cancer","NOT_YET_RECRUITING","2024-01-01",{"date":226,"type":37},"2024-01-11",{"date":228,"type":21},"2024-01-09",{"date":230,"type":21},"2031-06-30",{"name":43,"class":44},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":56,"phases":242,"briefSummary":243,"conditions":244,"keywords":247,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":45},"100530123","concurrent-oct-and-ffr-guided-pci-in-cad-100530123","NCT06182683","Concurrent OCT and FFR-guided PCI in CAD","Concurrent OPTIcal Coherence Tomography and frActional Flow REserve-guided Therapeutic Intervention in Patients With Coronary Artery Disease (OPTICARE-CAD)","OPTICARE-CAD","Inclusion Criteria:\n\n1. Age greater than 19 years old\n2. Patients undergoing coronary stent implantation for stable angina or acute coronary syndrome\n3. Patients provided on informed consent\n\nExclusion Criteria:\n\n1. Individuals with a history of increased bleeding tendencies or hematologic disorders\n2. Presented with refractory cardiogenic shock\n3. Individuals with a history of stent thrombosis\n4. Expected life expectancy of less than 1 year\n5. Left ventricular ejection fraction (LVEF) ≥ 20%\n6. Women who are breastfeeding, pregnant, or planning to become pregnant\n7. Deemed unsuitable for participation by the investigator\n8. Patients unwilling to participate in the clinical trial",{"count":241,"type":21},700,[58],"The present study is a prospective randomized clinical trial aimed to compare the therapeutic strategy of angiography-guided versus concurrent OCT\u002FFFR-guided intervention in patients with coronary artery disease.",[62,245,246],"Image","Atheroscleroses, Coronary",[64,248,249,250,251,252],"Fractional flow reserve","Angiography","Coronary artery disease","Percutaneous coronary intervention","Drug-eluting stent","2023-12-25",{"date":255,"type":37},"2023-12-27",{"date":257,"type":37},"2023-11-30",{"date":259,"type":21},"2029-12-31",{"name":43,"class":44},""]